Duration: 60 minutes
Continuing Education: This virtual workshop is eligible for 1 CE.
Speaker: Amy Stewart, MSN, RN, DNS-MT, QCP-MT, RAC-MT
Does the Drug Regimen Review (DRR) have you stumped? With so much confusion around DRR and medication reconciliation, it’s hard to know if you’re on the right track. Learn how best to comply with the Oct. 1, 2018, requirements for a DRR on section N of the MDS in this virtual workshop.
The DRR impacts the SNF QRP Quality Measure, which assesses whether or not a DRR was conducted upon admission, throughout the residents Medicare stay, and if potential or real clinically significant medication issues were followed up upon. Although the data is captured on the MDS, a sound process for conducting and documenting the review and follow-up is critical to your facility’s publicly reported QRP measure. This requires collaboration and communication between the NAC and DNS for successful and sustainable implementation. While the NAC is responsible for coding the item, he or she will depend on nurse leaders to ensure a solid system is in place to collect, follow-up on, and document on the required components.
During this 60-minute virtual workshop, the speaker will identify the elements of the SNF QRP drug regimen review Quality Measure. You’ll examine the process of gathering and reporting the findings of the drug regimen review on the MDS and look at the differences between the monthly medication reconciliation process outlined in the State Operations Manual (SOM) under F756 and MDS drug regimen review process. Finally, you’ll learn about the differences between the drug regimen review for SNF QRP and the one outlined in the SOM.
- Explain the process of medication reconciliation and drug regimen review, the timeline for completion and follow-up with physicians, and documentation requirements
- Describe the elements of the SNF QRP drug regimen review Quality Measure and detail how to ensure they are collected throughout the resident’s stay
- Explain what constitutes a potential or real clinically significant medication issue
- Compare and contrast the MDS drug regimen review and the F756 medication reconciliation found in the SOM